Rhumbline Advisers Acquires 3,400 Shares of Collegium Pharmaceutical, Inc. $COLL

Rhumbline Advisers grew its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 111,628 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,400 shares during the period. Rhumbline Advisers owned 0.35% of Collegium Pharmaceutical worth $3,332,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of COLL. Deutsche Bank AG raised its stake in Collegium Pharmaceutical by 12.2% during the 4th quarter. Deutsche Bank AG now owns 84,163 shares of the specialty pharmaceutical company’s stock valued at $2,411,000 after purchasing an additional 9,164 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Collegium Pharmaceutical by 1.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company’s stock worth $522,000 after buying an additional 339 shares during the last quarter. Millennium Management LLC grew its stake in Collegium Pharmaceutical by 38.8% during the fourth quarter. Millennium Management LLC now owns 185,918 shares of the specialty pharmaceutical company’s stock worth $5,327,000 after buying an additional 51,972 shares during the last quarter. ProShare Advisors LLC grew its stake in shares of Collegium Pharmaceutical by 28.8% during the fourth quarter. ProShare Advisors LLC now owns 11,196 shares of the specialty pharmaceutical company’s stock valued at $321,000 after purchasing an additional 2,506 shares during the last quarter. Finally, State of Wyoming grew its stake in shares of Collegium Pharmaceutical by 75.0% during the fourth quarter. State of Wyoming now owns 9,818 shares of the specialty pharmaceutical company’s stock valued at $281,000 after purchasing an additional 4,208 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on COLL shares. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. HC Wainwright upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 target price on the stock in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $42.33.

Collegium Pharmaceutical Stock Performance

Shares of COLL opened at $34.92 on Tuesday. The firm has a 50-day moving average of $35.08 and a 200-day moving average of $31.00. Collegium Pharmaceutical, Inc. has a one year low of $23.23 and a one year high of $42.29. The company has a market cap of $1.10 billion, a PE ratio of 33.58 and a beta of 0.63. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.18 and a quick ratio of 1.10.

Collegium Pharmaceutical declared that its Board of Directors has approved a stock repurchase plan on Monday, July 7th that permits the company to repurchase $150.00 million in shares. This repurchase authorization permits the specialty pharmaceutical company to purchase up to 15.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Insider Activity

In other news, Director John Gordon Freund sold 11,659 shares of Collegium Pharmaceutical stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $34.36, for a total value of $400,603.24. Following the completion of the transaction, the director owned 23,129 shares of the company’s stock, valued at $794,712.44. This trade represents a 33.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gino Santini sold 5,405 shares of Collegium Pharmaceutical stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $37.19, for a total transaction of $201,011.95. Following the sale, the director directly owned 95,042 shares of the company’s stock, valued at $3,534,611.98. The trade was a 5.38% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 55,792 shares of company stock worth $2,084,207. Insiders own 2.51% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.